Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs primarily for the treatment of cancer and other serious diseases. The company's product pipeline is centered around cell cycle control and transcriptional regulation mechanisms, targeting key oncology areas like leukemia and solid tumors. Cyclacel leverages its expertise in cancer biology to develop therapies that specifically inhibit enzymes critical for cancer cell proliferation. The company’s notable candidates include oral investigational drug seliciclib and CYC065, which have shown potential in preclinical and clinical studies to treat various cancers. Through developing these specialized treatments, Cyclacel Pharmaceuticals aims to address unmet medical needs and provide options for patients with limited alternatives, playing a significant role in oncology therapeutics. Operating within the highly regulated and competitive pharmaceutical industry, Cyclacel collaborates with academic institutions and other industry leaders to advance its research and expand its clinical programs. Headquartered in Berkeley Heights, New Jersey, Cyclacel continues to contribute to global cancer research and therapeutic options.